Cargando…

Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers

BACKGROUND: EGFR, KRAS, and ALK alterations are major genetic changes found in non-small cell lung cancers (NSCLCs). Testing advanced lung adenocarcinoma tumors for these three genes is now standard care. The purpose of this study was to investigate the clinicopathologic expression pattern of these...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Boram, Lee, Taebum, Lee, Se-Hoon, Choi, Yoon-La, Han, Joungho
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029670/ https://www.ncbi.nlm.nih.gov/pubmed/26992209 http://dx.doi.org/10.18632/oncotarget.8074

Ejemplares similares

Non-small Cell Lung Cancer with Concomitant EGFR, KRAS, and ALK Mutation: Clinicopathologic Features of 12 Cases
por: Lee, Taebum, et al.
Publicado: (2016)

MicroRNA expression profiles and clinicopathological implications in lung adenocarcinoma according to EGFR, KRAS, and ALK status
por: Kim, Hyojin, et al.
Publicado: (2016)

Clinicopathological characteristics and outcomes of ROS1-rearranged patients with lung adenocarcinoma without EGFR, KRAS mutations and ALK rearrangements
por: Wu, Shafei, et al.
Publicado: (2015)

Identification of somatic mutations in EGFR/KRAS/ALK-negative lung adenocarcinoma in never-smokers
por: Ahn, Jin Woo, et al.
Publicado: (2014)

Clinicopathological Characteristics of Primary Pulmonary Hodgkin Lymphoma (PPHL): Two Institutional Experiences with Comprehensive Literature Review of 115 PPHL Cases
por: Jung, Hera, et al.
Publicado: (2022)

Abrupt Dyskeratotic and Squamoid Cells in Poorly Differentiated Carcinoma: Case Study of Two Thoracic NUT Midline Carcinomas with Cytohistologic Correlation
por: Lee, Taebum, et al.
Publicado: (2018)

KRAS Mutation Detection in Non-small Cell Lung Cancer Using a Peptide Nucleic Acid-Mediated Polymerase Chain Reaction Clamping Method and Comparative Validation with Next-Generation Sequencing
por: Lee, Boram, et al.
Publicado: (2014)

Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations
por: Secq, V, et al.
Publicado: (2014)

EGFR, ALK, RET, KRAS and BRAF alterations in never-smokers with non-small cell lung cancer
por: DONG, YU, et al.
Publicado: (2016)

EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma
por: Colombino, Maria, et al.
Publicado: (2019)

Colorectal cancers with a residual adenoma component: Clinicopathologic features and KRAS mutation
por: Lee, Hyoun Wook, et al.
Publicado: (2022)

Analysis of the frequency of EGFR, KRAS and ALK mutations in patients with lung adenocarcinoma in Croatia
por: Brcic, Luka, et al.
Publicado: (2016)

Imaging Characteristics of Driver Mutations in EGFR, KRAS, and ALK among Treatment-Naïve Patients with Advanced Lung Adenocarcinoma
por: Park, Jangchul, et al.
Publicado: (2016)

Clinicopathological characteristics of primary lung nuclear protein in testis carcinoma: A single‐institute experience of 10 cases
por: Cho, Yoon Ah, et al.
Publicado: (2020)

Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression
por: Zhang, Xuchao, et al.
Publicado: (2010)

A case of concomitant EGFR/ALK alteration against a mutated EGFR background in early-stage lung adenocarcinoma
por: Lee, Ki-Chang, et al.
Publicado: (2021)

EGFR and KRAS mutations in pulmonary pleomorphic carcinoma and their correlation with clinicopathologic features
por: Jia, Xiaoli, et al.
Publicado: (2015)

Clinicopathological characteristics of ROS1- and RET-rearranged NSCLC in caucasian patients: Data from a cohort of 713 non-squamous NSCLC lacking KRAS/EGFR/HER2/BRAF/PIK3CA/ALK alterations
por: Dugay, Frédéric, et al.
Publicado: (2017)

Analysis of Histologic Features Suspecting Anaplastic Lymphoma Kinase (ALK)-Expressing Pulmonary Adenocarcinoma
por: Choi, In Ho, et al.
Publicado: (2015)

Real-World Analysis of the EGFR Mutation Test in Tissue and Plasma Samples from Non-Small Cell Lung Cancer
por: Lee, Hyunwoo, et al.
Publicado: (2021)

Clinicopathological characteristics with EGFR, ALK, ROS1 genetic alternation and prognostic analysis of primary lymphoepithelioma-like carcinoma
por: Shen, Yinchen, et al.
Publicado: (2019)

Anaplastic lymphoma kinase (ALK)-expressing Lung Adenocarcinoma with Combined Neuroendocrine Component or Neuroendocrine Transformation: Implications for Neuroendocrine Transformation and Response to ALK-tyrosine Kinase Inhibitors
por: Sim, Jongmin, et al.
Publicado: (2018)

Association with PD-L1 Expression and Clinicopathological Features in 1000 Lung Cancers: A Large Single-Institution Study of Surgically Resected Lung Cancers with a High Prevalence of EGFR Mutation
por: Lee, Seung Eun, et al.
Publicado: (2019)

Transformation to Small Cell Lung Cancer of Pulmonary Adenocarcinoma: Clinicopathologic Analysis of Six Cases
por: Ahn, Soomin, et al.
Publicado: (2016)

Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS
por: Korpanty, Grzegorz J., et al.
Publicado: (2014)

A Rare Case of Tumor-to-Tumor Metastasis of Thyroid Papillary Carcinoma within a Pulmonary Adenocarcinoma
por: Lee, Taebum, et al.
Publicado: (2015)

Combined Treatment with Botulinum Toxin and 595-nm Pulsed Dye Laser for Traumatic Scarring
por: Lee, Sang Ju, et al.
Publicado: (2015)

Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations
por: Lou, Na-Na, et al.
Publicado: (2016)

Prognostic Value of BIRC5 in Lung Adenocarcinoma Lacking EGFR, KRAS, and ALK Mutations by Integrated Bioinformatics Analysis
por: Cao, Yajuan, et al.
Publicado: (2019)

595. Characteristics of Antimicrobials Which Affect Parenteral Antibiotic Therapy Outcomes
por: Shah, haroon M, et al.
Publicado: (2020)

Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations
por: Lewis, Whitney E., et al.
Publicado: (2021)

Clinicopathological parameters for circulating tumor DNA shedding in surgically resected non-small cell lung cancer with EGFR or KRAS mutation
por: Cho, Min-Sun, et al.
Publicado: (2020)

Cytologic Features of ALK-Positive Pulmonary Adenocarcinoma
por: Ha, Seung Yeon, et al.
Publicado: (2013)

SEC31A-ALK Fusion Gene in Lung Adenocarcinoma
por: Kim, Ryong Nam, et al.
Publicado: (2016)

Potential Therapeutic Strategy for EGFR-Mutant Lung Cancer With Concomitant EML4-ALK Rearrangement—Combination of EGFR Tyrosine Kinase Inhibitors and ALK Inhibitors
por: Huang, Ming-Hung, et al.
Publicado: (2022)

Molecular Signatures of KRAS-Mutated Lung Adenocarcinoma: Analysis of Concomitant EGFR, ALK, STK11, and PD-L1 Status
por: Hsu, Jim, et al.
Publicado: (2022)

Solitary Pulmonary Capillary Hemangioma: CT and PET-CT Features with Clinicopathologic Correlation
por: Kim, Min Ju, et al.
Publicado: (2022)

595 Urticarial Rash Associated with Chest Pain
por: Boulaich, Mouna, et al.
Publicado: (2012)

CT features and disease spread patterns in ROS1-rearranged lung adenocarcinomas: comparison with those of EGFR-mutant or ALK-rearranged lung adenocarcinomas
por: Woo, Jung Han, et al.
Publicado: (2020)

Clinical and computed tomography characteristics of non‐small cell lung cancer with ALK gene rearrangement: Comparison with EGFR mutation and ALK/EGFR‐negative lung cancer
por: Mori, Mio, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_v1e1i1f35mi6qured7ro73k3m6